CARESIDE INC | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (34)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
Article By: ChinaBio® Today
Saturday, August 5, 2023 2:19 PM EDT
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize Oramed's oral drug delivery products globally.
In this article: ABVC, AZN, PFE, ORMP, CASI, LIAN
Read
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Article By: ChinaBio® Today
Saturday, July 22, 2023 12:39 PM EDT
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching research/license collaboration with BioNTech SE.
In this article: NVS Also: CASI, BNTX, VBIZF
Read
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Article By: ChinaBio® Today
Saturday, September 24, 2022 2:00 PM EDT
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma sold its 12% stake in its partner for $34 million.
In this article: 1177.HK, 2162.HK, 9995.HK, BLTE, 2315.HK Also: MRK, CASI, IVA
Read
Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs
Article By: ChinaBio® Today
Saturday, September 10, 2022 2:40 PM EDT
Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment.
In this article: CASI, 688222.SS, 6185.HK, 6998.HK, 688221.SS
Read
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments
Article By: ChinaBio® Today
Saturday, July 9, 2022 1:40 PM EDT
New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make investments in China’s healthcare and tech companies.
In this article: CASI, BGNE, 2137.HK
Read
All Posts

Latest Tweets for $CASI

No tweets yet!

PARTNER HEADLINES